{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:25:12Z","timestamp":1786951512865,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]},{"name":"Joint Program on Health Science & Technology Innovation of Hainan Province","award":["SQ2026WSJK0193"],"award-info":[{"award-number":["SQ2026WSJK0193"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10735-026-10880-6","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:19:07Z","timestamp":1783055947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRCC3 promotes progression and immune evasion in non-small cell lung cancer through regulation of PD-L1 and B7-H3"],"prefix":"10.1007","volume":"57","author":[{"given":"Kai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"10880_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, Bonaventure A, Valkov M, Johnson CJ, Est\u00e8ve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP (2018) Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023\u20131075. https:\/\/doi.org\/10.1016\/s0140-6736(17)33326-3","journal-title":"Lancet"},{"key":"10880_CR3","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.Ccr-16-3107","volume":"23","author":"M Altan","year":"2017","unstructured":"Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL (2017) B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Clin Cancer Res 23:5202\u20135209. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3107","journal-title":"Clin Cancer Res"},{"key":"10880_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"10880_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41423-019-0305-2","volume":"17","author":"D Cai","year":"2020","unstructured":"Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Li P, Lyu N, Sun T, Xie S, Guo L, Ni L, Jin L, Dong C (2020) Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol 17:227\u2013236. https:\/\/doi.org\/10.1038\/s41423-019-0305-2","journal-title":"Cell Mol Immunol"},{"key":"10880_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","volume":"7","author":"D Carvajal-Hausdorf","year":"2019","unstructured":"Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA (2019) Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer 7:65. https:\/\/doi.org\/10.1186\/s40425-019-0540-1","journal-title":"J Immunother Cancer"},{"key":"10880_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L (2001) B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2:269\u2013274. https:\/\/doi.org\/10.1038\/85339","journal-title":"Nat Immunol"},{"key":"10880_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17:54. https:\/\/doi.org\/10.1186\/s13045-024-01581-2","journal-title":"J Hematol Oncol"},{"key":"10880_CR1","unstructured":"Curade MP, Edwards B, Shin HR et al (2008) Cancer incidence in five continents. IX. IARC Sci Publ 1\u2013837"},{"key":"10880_CR9","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.7150\/thno.47137","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, Sun Y, Hu Y, Wu B, Wu G, Lovell JF, Jin H, Yang K (2020) USP7 targeting modulates anti-tumor immune response by reprogramming tumor-associated macrophages in lung cancer. Theranostics 10:9332\u20139347. https:\/\/doi.org\/10.7150\/thno.47137","journal-title":"Theranostics"},{"key":"10880_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50:1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"key":"10880_CR11","doi-asserted-by":"publisher","first-page":"101801","DOI":"10.1016\/j.tranon.2023.101801","volume":"39","author":"FP Fabrizio","year":"2024","unstructured":"Fabrizio FP, Muscarella LA, Rossi A (2024) B7-H3\/CD276 and small-cell lung cancer: what\u2019s new? Transl Oncol 39:101801. https:\/\/doi.org\/10.1016\/j.tranon.2023.101801","journal-title":"Transl Oncol"},{"key":"10880_CR12","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/jco.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37:2518\u20132527. https:\/\/doi.org\/10.1200\/jco.19.00934","journal-title":"J Clin Oncol"},{"key":"10880_CR13","doi-asserted-by":"publisher","unstructured":"Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S (2023) Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7-H3 and B7-H4 in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Cells. https:\/\/doi.org\/10.3390\/cells12060832","DOI":"10.3390\/cells12060832"},{"key":"10880_CR14","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.12-2359","volume":"143","author":"JA Howington","year":"2013","unstructured":"Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC (2013) Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e278S\u2013e313. https:\/\/doi.org\/10.1378\/chest.12-2359. S","journal-title":"Chest"},{"key":"10880_CR15","doi-asserted-by":"publisher","first-page":"1133200","DOI":"10.3389\/fonc.2023.1133200","volume":"13","author":"X Hu","year":"2023","unstructured":"Hu X, Wu J, Xu J (2023) UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p\/BRCC3. Front Oncol 13:1133200. https:\/\/doi.org\/10.3389\/fonc.2023.1133200","journal-title":"Front Oncol"},{"key":"10880_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3324\/haematol.2014.111989","volume":"100","author":"D Huang","year":"2015","unstructured":"Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H (2015) BRCC3 mutations in myeloid neoplasms. Haematologica 100:1051\u20131057. https:\/\/doi.org\/10.3324\/haematol.2014.111989","journal-title":"Haematologica"},{"key":"10880_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3724\/abbs.2024005","volume":"56","author":"Q Huang","year":"2024","unstructured":"Huang Q, Zheng S, Gu H, Yang Z, Lu Y, Yu X, Guo G (2024) The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 56:564\u2013575. https:\/\/doi.org\/10.3724\/abbs.2024005","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10880_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.Ccr-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S (2021) B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res 27:1227\u20131235. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2584","journal-title":"Clin Cancer Res"},{"key":"10880_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bcp.12164","volume":"76","author":"CS Lee","year":"2013","unstructured":"Lee CS, Cragg M, Glennie M, Johnson P (2013) Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 76:233\u2013247. https:\/\/doi.org\/10.1111\/bcp.12164","journal-title":"Br J Clin Pharmacol"},{"key":"10880_CR21","doi-asserted-by":"publisher","first-page":"71725","DOI":"10.18632\/oncotarget.17847","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Yang X, Wu Y, Zhao K, Ye Z, Zhu J, Xu X, Zhao X, Xing C (2017) B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget 8:71725\u201371735. https:\/\/doi.org\/10.18632\/oncotarget.17847","journal-title":"Oncotarget"},{"key":"10880_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.21037\/jtd.2020.04.41","volume":"12","author":"F Li","year":"2020","unstructured":"Li F, Chen H, Wang D (2020) Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling. J Thorac Dis 12:2137\u20132145. https:\/\/doi.org\/10.21037\/jtd.2020.04.41","journal-title":"J Thorac Dis"},{"key":"10880_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"10880_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, Lu B, Fan Y, Liu Z, Chen X, Jia X, Dong Z, Liu K (2024) Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer 23:148. https:\/\/doi.org\/10.1186\/s12943-024-02046-3","journal-title":"Mol Cancer"},{"key":"10880_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2018.07.018","volume":"434","author":"SF Nabavi","year":"2018","unstructured":"Nabavi SF, Atanasov AG, Khan H, Barreca D, Trombetta D, Testai L, Sureda A, Tejada S, Vacca RA, Pittal\u00e0 V, Gulei D, Berindan-Neagoe I, Shirooie S, Nabavi SM (2018) Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: lessons learned from clinical trials. Cancer Lett 434:101\u2013113. https:\/\/doi.org\/10.1016\/j.canlet.2018.07.018","journal-title":"Cancer Lett"},{"key":"10880_CR25","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/s1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015) Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16:e165\u2013e172. https:\/\/doi.org\/10.1016\/s1470-2045(14)71180-5","journal-title":"Lancet Oncol"},{"key":"10880_CR26","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1038\/s41467-023-43548-w","volume":"14","author":"S Shang","year":"2023","unstructured":"Shang S, Yang C, Chen F, Xiang RS, Zhang H, Dai SY, Liu J, Lv XX, Zhang C, Liu XT, Zhang Q, Lu SB, Song JW, Yu JJ, Zhou JC, Zhang XW, Cui B, Li PP, Zhu ST, Zhang HZ, Hua F (2023) ID1 expressing macrophages support cancer cell stemness and limit CD8(+) T cell infiltration in colorectal cancer. Nat Commun 14:7661. https:\/\/doi.org\/10.1038\/s41467-023-43548-w","journal-title":"Nat Commun"},{"key":"10880_CR27","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.jbc.2021.101077","volume":"297","author":"NA Snyder","year":"2021","unstructured":"Snyder NA, Silva GM (2021) Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response. J Biol Chem 297:101077. https:\/\/doi.org\/10.1016\/j.jbc.2021.101077","journal-title":"J Biol Chem"},{"key":"10880_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3892\/or.2016.4808","volume":"36","author":"ZZ Sun","year":"2016","unstructured":"Sun ZZ, Zhang T, Ning K, Zhu R, Liu F, Tang SC, Jiang B, Hua D (2016) B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. Oncol Rep 36:231\u2013238. https:\/\/doi.org\/10.3892\/or.2016.4808","journal-title":"Oncol Rep"},{"key":"10880_CR29","doi-asserted-by":"publisher","first-page":"720349","DOI":"10.3389\/fcell.2021.720349","volume":"9","author":"H Tao","year":"2021","unstructured":"Tao H, Liao Y, Yan Y, He Z, Zhou J, Wang X, Peng J, Li S, Liu T (2021) BRCC3 promotes tumorigenesis of bladder cancer by activating the NF-\u03baB signaling pathway through targeting TRAF2. Front Cell Dev Biol 9:720349. https:\/\/doi.org\/10.3389\/fcell.2021.720349","journal-title":"Front Cell Dev Biol"},{"key":"10880_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13014-015-0427-3","volume":"10","author":"Z Tu","year":"2015","unstructured":"Tu Z, Xu B, Qu C, Tao Y, Chen C, Hua W, Feng G, Chang H, Liu Z, Li G, Jiang C, Yi W, Zeng M, Xia Y (2015) BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. Radiat Oncol 10:123. https:\/\/doi.org\/10.1186\/s13014-015-0427-3","journal-title":"Radiat Oncol"},{"key":"10880_CR32","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1172\/jci85747","volume":"126","author":"Q Wang","year":"2016","unstructured":"Wang Q, Ma S, Song N, Li X, Liu L, Yang S, Ding X, Shan L, Zhou X, Su D, Wang Y, Zhang Q, Liu X, Yu N, Zhang K, Shang Y, Yao Z, Shi L (2016) Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J Clin Invest 126:2205\u20132220. https:\/\/doi.org\/10.1172\/jci85747","journal-title":"J Clin Invest"},{"key":"10880_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fimmu.2020.00681","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang C, Feng H, Cheng X, Liu K, Cai D, Zhao R (2020) Potential therapeutic targets of B7 family in colorectal cancer. Front Immunol 11:681. https:\/\/doi.org\/10.3389\/fimmu.2020.00681","journal-title":"Front Immunol"},{"key":"10880_CR33","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/s41467-023-38605-3","volume":"14","author":"X Xiao","year":"2023","unstructured":"Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, Xiang B, Xiong W, Dai P, Mao Q, Xing X, Yao Y, Yu H, Xu G, Li S, Ren Y, Chen B, Jiang C, Meng G, Lee YR, Wei W, Freeman GJ, Xie C, Zhang J (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun 14:2859. https:\/\/doi.org\/10.1038\/s41467-023-38605-3","journal-title":"Nat Commun"},{"key":"10880_CR34","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1161\/circulationaha.123.065344","volume":"148","author":"M Yalcinkaya","year":"2023","unstructured":"Yalcinkaya M, Liu W, Thomas LA, Olszewska M, Xiao T, Abramowicz S, Papapetrou EP, Westerterp M, Wang N, Tabas I, Tall AR (2023) BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis. Circulation 148:1764\u20131777. https:\/\/doi.org\/10.1161\/circulationaha.123.065344","journal-title":"Circulation"},{"key":"10880_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.7150\/ijbs.41105","volume":"16","author":"S Yang","year":"2020","unstructured":"Yang S, Wei W, Zhao Q (2020) B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci 16:1767\u20131773. https:\/\/doi.org\/10.7150\/ijbs.41105","journal-title":"Int J Biol Sci"},{"key":"10880_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41418-022-01102-z","volume":"30","author":"H Yang","year":"2023","unstructured":"Yang H, Zhang X, Lao M, Sun K, He L, Xu J, Duan Y, Chen Y, Ying H, Li M, Guo C, Lu Q, Wang S, Su W, Liang T, Bai X (2023) Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Cell Death Differ 30:560\u2013575. https:\/\/doi.org\/10.1038\/s41418-022-01102-z","journal-title":"Cell Death Differ"},{"key":"10880_CR37","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.3892\/mmr.2018.9511","volume":"18","author":"F Zhang","year":"2018","unstructured":"Zhang F, Zhou Q (2018) Knockdown of BRCC3 exerts an anti-tumor effect on cervical cancer in vitro. Mol Med Rep 18:4886\u20134894. https:\/\/doi.org\/10.3892\/mmr.2018.9511","journal-title":"Mol Med Rep"},{"key":"10880_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/1873-3468.13970","volume":"595","author":"W Zhang","year":"2021","unstructured":"Zhang W, Tao SS, Wang T, Zhang J, Liu X, Li YT, Chen H, Zhan YQ, Yu M, Ge CH, Li CY, Ren GM, Yang XM, Yin RH (2021) ABRO1 stabilizes the deubiquitinase BRCC3 through inhibiting its degradation mediated by the E3 ubiquitin ligase WWP2. FEBS Lett 595:169\u2013182. https:\/\/doi.org\/10.1002\/1873-3468.13970","journal-title":"FEBS Lett"},{"key":"10880_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, Li H, Xia Y, Wang Y, Wang Y, Shi Y, Xing H, Qu T, Wang Y, Ma W (2022) Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol 15:153. https:\/\/doi.org\/10.1186\/s13045-022-01364-7","journal-title":"J Hematol Oncol"},{"key":"10880_CR40","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou WT, Jin WL (2021) B7-H3\/CD276: an emerging cancer immunotherapy. Front Immunol 12:701006. https:\/\/doi.org\/10.3389\/fimmu.2021.701006","journal-title":"Front Immunol"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10880-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-10880-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10880-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:49:25Z","timestamp":1786949365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-026-10880-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10880"],"URL":"https:\/\/doi.org\/10.1007\/s10735-026-10880-6","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Hainan General Hospital, Hainan Medical University Hainan Hospital.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}